Profile data is unavailable for this security.
About the company
Recce Pharmaceuticals Ltd is an Australia-based company engaged in the development and commercialization of a new class of synthetic anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. The Company's anti-infective pipeline includes three broad-spectrum, synthetic polymer anti-infectives: RECCE 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE 435 as an orally administered therapy for bacterial infections; and RECCE 529 for viral infections. Through their multi-layered mechanisms of action, the Company's anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses. All RECCE compounds are water soluble at all pH levels in their liquid form.
- Revenue in AUD (TTM)5.24m
- Net income in AUD-17.66m
- Incorporated2007
- Employees--
- LocationRecce Pharmaceuticals LtdLevel 23180 George St, Salesforce TowerSYDNEY 2000AustraliaAUS
- Phone+61 29256-2505
- Fax+61 28075-4584
- Websitehttps://www.recce.com.au/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Radiopharm Theranostics Ltd | 299.23k | -47.95m | 69.53m | -- | -- | 0.5238 | -- | 232.38 | -0.1261 | -0.1261 | 0.0008 | 0.0611 | 0.0041 | -- | 0.1097 | -- | -65.24 | -- | -82.85 | -- | -- | -- | -16,024.17 | -- | -- | -3.46 | -- | -- | 2.35 | -- | -38.54 | -- | -- | -- |
| PharmAust Limited | 866.18k | -8.90m | 87.56m | 52.00 | -- | 7.83 | -- | 101.08 | -0.0234 | -0.0199 | 0.0023 | 0.023 | 0.1004 | -- | 10.39 | -- | -103.16 | -31.15 | -118.57 | -35.11 | -- | -- | -1,027.49 | -105.37 | -- | -- | 0.00 | -- | -8.78 | -27.63 | -466.09 | -- | -- | -- |
| Recce Pharmaceuticals Ltd | 5.24m | -17.66m | 114.65m | -- | -- | -- | -- | 21.89 | -0.0999 | -0.0999 | 0.0296 | -0.0467 | 1.17 | -- | 41.87 | -- | -395.76 | -136.12 | -- | -226.28 | -- | -- | -337.29 | -373.28 | -- | -19.86 | -- | -- | 18.17 | 50.13 | -35.06 | -- | 9.55 | -- |
| EZZ Life Science Holdings Ltd | 66.44m | 6.96m | 128.80m | -- | 18.04 | 6.04 | 17.51 | 1.94 | 0.1607 | 0.1607 | 1.54 | 0.4801 | 3.08 | 13.79 | 33.30 | -- | 32.25 | 24.12 | 38.61 | 31.19 | 76.67 | 65.40 | 10.48 | 9.81 | 5.63 | 482.42 | 0.0058 | -- | 78.88 | 42.81 | 91.87 | 53.25 | 176.34 | -- |
| Vita Life Sciences Limited | 78.92m | 9.41m | 131.97m | 124.00 | 13.63 | 2.71 | 13.35 | 1.67 | 0.1717 | 0.1717 | 1.44 | 0.865 | 1.29 | 2.33 | 6.94 | -- | 15.37 | 15.25 | 21.18 | 21.99 | 58.48 | 60.90 | 11.90 | 11.71 | 2.18 | -- | 0.0088 | 39.05 | 10.88 | 12.50 | 28.18 | 30.07 | 12.15 | 19.14 |
| Biome Australia Ltd | 13.07m | -1.67m | 168.72m | 30.00 | -- | 57.04 | -- | 12.91 | -0.0082 | -0.0082 | 0.0628 | 0.0135 | 1.65 | 2.08 | 6.06 | -- | -21.09 | -70.48 | -43.35 | -106.49 | 61.01 | 60.22 | -12.78 | -61.42 | 1.13 | -10.02 | 0.4829 | -- | 76.05 | 103.19 | 45.75 | -- | -47.07 | -- |
| Holder | Shares | % Held |
|---|---|---|
| FIL Investment Management (Hong Kong) Ltd.as of 31 Jul 2024 | 14.21m | 6.14% |
